Selinexor Plus Ruxolitinib in Janus Kinase Inhibitor–Naïve Myelofibrosis: Phase III SENTRY Trial

Journal:

Journal of Clinical Oncology

Published:

2026-06-03

DOI:

10.1200/jco-26-01080

Affiliations:

23

Authors:

163

Go to article

Institutions	Authors	Share
Karyopharm Therapeutics Inc., United States of America (USA)	5.000000	0.21
National Taiwan University Hospital (NTUH), Taiwan	1.000000	0.04
CHU Nice, France	1.000000	0.04
Guy's and St Thomas' NHS Foundation Trust, United Kingdom (UK)	1.000000	0.04
Medical University of Plovdiv, Bulgaria	1.000000	0.04
Seoul National University Hospital (SNUH), South Korea	1.000000	0.04
Iuliu Hațieganu University of Medicine and Pharmacy (UMF Cluj), Romania	1.000000	0.04
Medical University of Silesia (SUM), Poland	1.000000	0.04
Yale University, United States of America (USA)	1.000000	0.04
Memorial Sloan Kettering Cancer Center (MSKCC), United States of America (USA)	1.000000	0.04
Huntsman Cancer Institute at the University of Utah (HCI), Utah, United States of America (USA)	1.000000	0.04
City of Hope, United States of America (USA)	1.000000	0.04
The University of Alabama at Birmingham (UAB), United States of America (USA)	1.000000	0.04
Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Spain	1.000000	0.04
Aidport Clinical Trials Hospital, Poland	1.000000	0.04
University Hospital in Halle (Saale) (UKH), MLU, Germany	1.000000	0.04
The University of Texas MD Anderson Cancer Center, United States of America (USA)	1.000000	0.04
Icahn School of Medicine at Mount Sinai (ISMMS), MSHS, United States of America (USA)	1.000000	0.04
Hospital "Maggiore della Carità", Italy	0.500000	0.02
University of Eastern Piedmont "Amedeo Avogadro" (UPO), Italy	0.500000	0.02
IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Italy	0.500000	0.02
University of Milan (UNIMI), Italy	0.500000	0.02